PT1000541E - MEDICAL SOLUTION DEFINED ISSELF OF SERUM FOR OPHTHALMOLOGY - Google Patents

MEDICAL SOLUTION DEFINED ISSELF OF SERUM FOR OPHTHALMOLOGY

Info

Publication number
PT1000541E
PT1000541E PT99308702T PT99308702T PT1000541E PT 1000541 E PT1000541 E PT 1000541E PT 99308702 T PT99308702 T PT 99308702T PT 99308702 T PT99308702 T PT 99308702T PT 1000541 E PT1000541 E PT 1000541E
Authority
PT
Portugal
Prior art keywords
supplements
nutrient
ophthalmology
growth factor
medical solution
Prior art date
Application number
PT99308702T
Other languages
Portuguese (pt)
Inventor
Debra L Skelnik
Original Assignee
Debra L Skelnik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debra L Skelnik filed Critical Debra L Skelnik
Publication of PT1000541E publication Critical patent/PT1000541E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dentistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements, and a growth factor(s) which maintains and enhances the preservation of eye tissues, including human corneal, retinal and corneal epithelial tissues at low to physiological temperatures (2 DEG C to 38 DEG C). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s),a deturgescent agent(s), an energy source(s), a buffer system(s),an antioxidant(s), membrane stabilizing agents, an antibiotic(s) and/or antimycotic agent(s), ATP or energy precursors, nutrient cell supplements, coenzymes and enzyme supplements, nucleotide precursors, hormonal supplements, non-essential amino acids, trace minerals, trace elements and a growth factor(s). <IMAGE>
PT99308702T 1998-11-05 1999-11-02 MEDICAL SOLUTION DEFINED ISSELF OF SERUM FOR OPHTHALMOLOGY PT1000541E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/186,580 US6153582A (en) 1998-11-05 1998-11-05 Defined serumfree medical solution for ophthalmology

Publications (1)

Publication Number Publication Date
PT1000541E true PT1000541E (en) 2004-08-31

Family

ID=22685497

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99308702T PT1000541E (en) 1998-11-05 1999-11-02 MEDICAL SOLUTION DEFINED ISSELF OF SERUM FOR OPHTHALMOLOGY

Country Status (9)

Country Link
US (1) US6153582A (en)
EP (1) EP1000541B1 (en)
JP (1) JP2000198701A (en)
AT (1) ATE257648T1 (en)
AU (1) AU769082B2 (en)
CA (1) CA2288540C (en)
DE (1) DE69914160T2 (en)
ES (1) ES2217700T3 (en)
PT (1) PT1000541E (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849612B2 (en) * 1993-01-21 2005-02-01 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US6974796B1 (en) 1999-08-17 2005-12-13 Girsh Leonard S Therapeutic compositions for treatment of a damaged tissue
US20070231402A1 (en) 1994-08-02 2007-10-04 Immunopath Profile, Inc. Therapeutic stem cell composition and stimulant, facilitator, accelerator, and synergizer thereof, growth factor, anti-inflammatory composition and uses thereof
US7790678B1 (en) * 1999-08-17 2010-09-07 Immunopath Profile, Inc. Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use
US20070037777A1 (en) * 2005-08-12 2007-02-15 Immunopath Profile, Inc. Lipid-containing compositions and methods of using them
US20090274660A1 (en) 1999-08-17 2009-11-05 Immunopath Profile, Inc. Pluripotent therapeutic compositions and uses thereof
WO2001056594A1 (en) 2000-02-04 2001-08-09 Unigene Laboratories, Inc. Nasal calcitonin formulations
US7611830B2 (en) * 2000-04-10 2009-11-03 The United States Of America As Represented By The Department Of Veteran's Affairs Device to lavage a blood vessel
US6569615B1 (en) * 2000-04-10 2003-05-27 The United States Of America As Represented By The Department Of Veteran's Affairs Composition and methods for tissue preservation
US6762053B2 (en) * 2000-06-09 2004-07-13 Vitrolife, Inc. Mammalian gamete and embryo culture media and culture media supplements
CN1262274C (en) * 2000-11-14 2006-07-05 生命健康科学有限公司 Complexes of phosphate derivatives
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
DE10133196A1 (en) * 2001-07-07 2003-01-23 Beiersdorf Ag Use of topical compositions containing nicotinic acid or its precursors, derivatives or metabolites e.g. to improve skin condition and to treat or prevent skin disorders
BR0211673A (en) 2001-07-27 2004-07-13 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
US20030077566A1 (en) * 2001-09-10 2003-04-24 Palasz Andrzej T. Method for cryopreserving mammalian cells and tissues
EP1441989A2 (en) * 2001-11-16 2004-08-04 Technocon GmbH Method for biological water treatment by addition of macromolecular carbohydrates
CA2473360A1 (en) * 2002-01-25 2003-08-07 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
EP1480520A4 (en) * 2002-02-12 2006-02-15 Raven Biotechnologies Inc Human fetal bladder-derived epithelial cells
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
EP1475434A1 (en) * 2003-05-09 2004-11-10 Oncoscience AG Method for storing tumor cells
FR2856891B1 (en) * 2003-07-04 2007-09-07 Stem Alpha ENVIRONMENT FOR PRESERVING ORGANS, BIOLOGICAL TISSUES OR LIVING CELLS
US20050176144A1 (en) * 2004-02-06 2005-08-11 O'daly Jose A. Culture media compositions free of fetal bovine serum
WO2005084678A1 (en) 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Alkaloid formulations
BRPI0400935A (en) * 2004-04-02 2005-11-22 Ernesto Rodriguez Salas Solution for conservation of biological membranes and their use
JP2005306749A (en) * 2004-04-19 2005-11-04 Kringle Pharma Inc Hgf-containing preserving liquid for organ
US8252591B2 (en) 2004-05-07 2012-08-28 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
CA2598792A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
WO2006110552A2 (en) * 2005-04-12 2006-10-19 Cleo Cosmetic And Pharmaceutical Co., Llc Composition and method for in vitro preservation of corneal tissues
KR20080019228A (en) 2005-06-17 2008-03-03 바이탈 헬스 사이언시즈 피티와이 리미티드 A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CN100362098C (en) * 2005-09-29 2008-01-16 华东理工大学 Non-serum culture medium for multiple animal cell large-scale culture
US20070224588A1 (en) * 2006-03-22 2007-09-27 Biocept, Inc. Trophoblast preservation/pretreatment medium and method
WO2007138119A1 (en) * 2006-05-30 2007-12-06 Instituto Nacional De Investigación Y Tecnología Agraria Y Alimentaria, Inia Procedure for the preparation of unilamellar vesicles for cryopreservation and the culture of stem cells and embryos
CN100463681C (en) * 2006-10-24 2009-02-25 北京紫竹药业有限公司 Artificial tears for treating xerophthalmia
AU2008216612B2 (en) * 2007-02-17 2014-12-04 President And Fellows Of Harvard College Compositions and method for tissue preservation
US20110244502A1 (en) * 2007-08-10 2011-10-06 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
WO2009105164A2 (en) 2008-02-15 2009-08-27 President And Fellows Of Harvard College Blood substitute solution
JP5663841B2 (en) * 2009-02-23 2015-02-04 富士レビオ株式会社 Medium for inducing differentiation into bone cells and method
CN101524063B (en) * 2009-03-23 2012-06-13 姚晓明 Cornea mid-term preservation liquid
PL2451299T3 (en) 2009-07-10 2016-09-30 Methods and compositions for treating thyroid-related medical conditions with reduced folates
FR2948286B1 (en) * 2009-07-27 2011-08-26 Jean-Noel Thorel INJECTABLE COMPOSITION COMPRISING A FILLING AGENT AND A FIBROBLAST GROWTH MEDIUM
JP5681472B2 (en) * 2009-12-28 2015-03-11 ロート製薬株式会社 Ophthalmic composition
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
EP2547760A4 (en) * 2010-02-17 2014-01-01 Hememics Biotechnologies Inc Preservation solutions for biologics and methods related thereto
CN102821791B (en) 2010-03-30 2015-06-17 磷肌酸有限公司 Transdermal delivery patch
US9845457B2 (en) * 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd Amino-quinolines as kinase inhibitors
AU2012283667B2 (en) 2011-07-12 2015-07-09 Foodchek Systems, Inc. Culture medium, method for culturing Salmonella and E. coli and method for detecting Salmonella and E. coli
EP2882445B1 (en) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
CA3153463A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
MX2015008529A (en) * 2012-12-31 2016-02-10 Somahlution Llc Solution for preserving vascular conduits.
CN103190392B (en) * 2013-03-28 2015-07-29 北京大学第三医院 A kind of cornea middle term preserving fluid and preparation method thereof
US10350232B1 (en) 2013-11-04 2019-07-16 Peter D. Jaillet Medicinal drops
SG10201709595WA (en) 2013-11-22 2017-12-28 Somahlution Llc Solutions for increasing the stability and shelf life of an organ and tissue preservation solution
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
JP6674462B2 (en) * 2014-12-02 2020-04-01 アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． Systems, methods and compositions for ocular crosslinking treatment
WO2016129654A1 (en) * 2015-02-12 2016-08-18 国立大学法人 東京大学 Method for preparing corneal endothelial precursor cells
ITUB20150108A1 (en) * 2015-03-04 2016-09-04 Alchilife S R L Synthetic antifungal molecule and method of synthesizing an antifungal molecule
WO2016159773A1 (en) 2015-04-03 2016-10-06 Tx Innovations B.V. Organ preservation composition
FR3035407B1 (en) 2015-04-23 2022-06-17 Francais Du Sang Ets METHOD FOR PRESERVING CELLS, TISSUES OR ORGANS IN HYPOTHERMIA
FR3040860B1 (en) * 2015-09-10 2020-05-15 Universite de Bordeaux INJECTABLE STORAGE MEDIUM FOR STORAGE OF PLACENTAL BLOOD, BONE MARROW AND PERIPHERAL BLOOD CELLS
CA3007587C (en) 2015-12-09 2023-12-05 Phosphagenics Limited Pharmaceutical formulation
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10426796B2 (en) 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
BR112019012946A2 (en) 2016-12-21 2019-11-26 Avecho Biotechnology Ltd process
US10265312B1 (en) * 2018-02-01 2019-04-23 Jason Ahee Antibiotic solution and method of injection to prevent ophthalmic infections
AU2018255346B2 (en) 2017-04-19 2024-05-02 Capricor Inc Methods and compositions for treating skeletal muscular dystrophy
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CN108841780B (en) * 2018-06-29 2019-03-12 陕西诺威利华生物科技有限公司 It is suitble to the serum free medium of large-scale production PEDV vaccine
CN109801994B (en) * 2019-01-09 2020-11-24 成都中建材光电材料有限公司 Method for improving performance of cadmium telluride cell
WO2020180985A1 (en) * 2019-03-04 2020-09-10 University Of Iowa Research Foundation Composition comprising an anti-oxidant to preserve corneal tissue
CN110278940A (en) * 2019-07-11 2019-09-27 河南省农业科学院畜牧兽医研究所 A kind of Boar spermatozoa preservative agent and its preparation method and application
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN112602703B (en) * 2020-12-17 2022-05-27 中山大学附属第三医院 Preparation method and application of cold preservation solution for cells, tissues or organs
CN113508807B (en) * 2021-08-05 2022-03-04 信阳农林学院 Ovarian normal-temperature preservation solution and preservation method thereof
CN114190366B (en) * 2021-12-29 2023-04-07 松山湖材料实验室 Frozen stock solution, preparation method thereof and application thereof in normal human liver cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1263606A (en) * 1985-05-29 1989-12-05 Jeffrey P. Gilbard Non-toxic opthalmic preparations
CA2041828A1 (en) * 1990-03-05 1992-11-04 Richard L. Lindstrom Viscoelastic solution
EP0516901A1 (en) * 1991-06-06 1992-12-09 Richard L. Lindstrom Method and apparatus of a serumfree medical solution

Also Published As

Publication number Publication date
JP2000198701A (en) 2000-07-18
AU5710899A (en) 2000-05-11
CA2288540C (en) 2011-07-05
EP1000541B1 (en) 2004-01-14
ES2217700T3 (en) 2004-11-01
DE69914160D1 (en) 2004-02-19
CA2288540A1 (en) 2000-05-05
ATE257648T1 (en) 2004-01-15
EP1000541A1 (en) 2000-05-17
AU769082B2 (en) 2004-01-15
DE69914160T2 (en) 2004-09-02
US6153582A (en) 2000-11-28

Similar Documents

Publication Publication Date Title
PT1000541E (en) MEDICAL SOLUTION DEFINED ISSELF OF SERUM FOR OPHTHALMOLOGY
ES2080254T3 (en) DEFINED SERUM-FREE MEDICAL SOLUTION AND ITS USE.
US4696917A (en) Irrigation solution
Ross et al. Enzymes of the γ-glutamyl cycle in the ciliary body and lens
Edelhauser et al. Intraocular irrigating solutions: their effect on the corneal endothelium
KR101490851B1 (en) Aqueous moisturizers and lubricants and uses thereof
IL190542A0 (en) Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US5221537A (en) Tissue irrigating solutions
ES2162331T3 (en) USE OF THE NERVOUS TISSUE GROWTH FACTOR FOR CONSERVATION, CROP OR TREATMENT OF THE CORNEA.
US5328701A (en) Tissue irrigation solution
Karlan et al. Potentiation of infections by biomaterials: a comparison of three materials
CN107296041A (en) A kind of fresh amnion preserves liquid and fresh amnion store method and application
WO2009086073A1 (en) Stabilized glycerophosphate-containing surgical irrigating solution
US20070087320A1 (en) Medium for conservation of organs, biological tissues or living cells
EP1125575B1 (en) Perfusate preparation for ophthalmic operation
US5380537A (en) Single irrigating solution used in ocular therapy for the endothelium protection and cornea preservation
CA2044494A1 (en) Methods and apparatus of a defined serumfree medical solution
BRPI9913018A (en) process for the preparation of active somatotropin from inclusion bodies.
JPH1025201A (en) Preservative liquid for dental germ
TW201200132A (en) Surgical compositions containing sigma-receptor agonists
Simon Reply of the author
Akanji et al. Effect of repeated administration of suramin on alkaline phosphatase activity in rat kidney.
Thoene et al. Cystine depletion of cystinotic cells by aminothiols
Winkler Comparison of intraocular solutions on glycolysis and levels of ATP and glutathione in the retina
Hull et al. Effect of urokinase on corneal endothelium